Amygdala Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for ANS-858

RegulatoryapprovedANS-858Positive

AI Analysis

Summary

Amygdala Neurosciences announced FDA clearance of the IND application for ANS-858, an ALDH2 inhibitor being developed to treat pathological craving in alcohol and substance use disorders, with potential applications in binge eating, obesity, and oncology.

Outcome Details

FDA Clearance of Investigational New Drug (IND) Application

Importance:6/10

Sentiment:

0.70

IND clearanceALDH2 inhibitorsubstance use disorderregulatory approval

Related Companies

$DTIL $INTI $DFPH

Read the original article

Published by PR Newswire Biotech on August 18, 2026 7:00 AM

Read Original